-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4296 Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Hematology Disease Topics & Pathways:
Genomics, Diseases, Biological Processes, Myeloid Malignancies
Monday, December 9, 2024, 6:00 PM-8:00 PM

Jae-Sook Ahn, M.D., Ph.D.1,2, Joo Heon Park, MD3*, Ik Chan Song, MD, PhD4, ChangSun Lee5*, Sang Kyun Sohn, MD, PhD6*, Ho-Young Yhim, MD7*, Yong Park, MD, PhD8, Inho Kim, MD, PhD9*, Ho-Jin Shin, MD10*, Seong Kyu Park, MD11*, Sung-Hyun Kim, MD12*, June-Won Cheong, MD, PhD13, Ho Sup Lee, MD, PhD14*, Hyewon Lee, MD15*, Sung Hwa Bae, MD16*, Yunsuk Choi, MD, PhD17, Hong-Ghi Lee18*, Young Rok Do, MD, PhD19, Jae-Joon Han20*, Min Kyoung Kim21*, Silvia Park, MD, PhD22*, Hee-Je Kim, MD, PhD22 and Hyeoung-Joon Kim, MD, PhD2,23

1Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)
2Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)
3Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)
4Department of Internal Medicine, College of Medicine, Chungnam National University Hospital, Daejeon, South Korea
5BI team, NGeneBio, Seoul, Korea, Republic of (South)
6Kyungpook National University Hospital, Daegu, Korea, Republic of (South)
7Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea, Republic of (South)
8Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea, Republic of (South)
9Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
10Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of (South)
11Department of Hematology/Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of (South)
12Department of Internal Medicine, Dong-A University Medical Center, Busan, Korea, Republic of (South)
13Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul, Korea, Republic of (South)
14Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea, Republic of (South)
15National Cancer Center, Goyang, KOR
16Department of Internal Medicine, Daegu Catholic, University Hospital, Daegu Catholic University School of Medicine, Daegu, KOR
17Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
18Internal medicine, Konkuk University, Konkuk University Medical Center, Seoul, Korea, Republic of (South)
19Department of Hemato-Oncology, Dongsan Medical Center, Keimyung University, Daegu, Korea, Republic of (South)
20Internal Medicine, Kyung Hee University,Kyung Hee University Medical Center, Seoul, Korea, Republic of (South)
21Yeungnam University College of Medicine, Daegu, Korea, Daegu, Korea, Republic of (South)
22Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
23Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)

Somatic next-generation sequencing (NGS) panel are now routinely performed at diagnosis of acute myeloid leukemia (AML) to identify genetic variants for risk stratification and treatment decisions. The variant allele frequencies (VAF) suspected to be germline variants remain persistently high in complete remission (CR) state, allowing these variants to be identified as germline variants. The NGS panel used clinically for diagnosis includes representative genes associated with germline predisposition to myeloid neoplasms. Based on above information, we aimed to investigate the frequency of germline variants and their prognostic significance of AML in patients with matched samples at diagnosis and at CR state. We conducted a prospective multicenter study (KCT0004825) collecting serial samples from AML patients. The process of interpreting germline variants is performed according to the American College of Medical Genetics and Genomics (ACMG) variant interpretation guidelines. We classified germline variants as causality if they were either ‘Pathogenic’ or ‘Likely Pathogenic’ by the ACMG guideline or if they were accompanied by a somatic mutation with ‘Variants of Uncertain Significance’.

This study enrolled 603 patients diagnosed with treatable AML, excluding acute promyelocytic leukemia, between Feb. 2017 and Jun. 2021 from 17 institutions. Among these, paired CR samples were available for 343 patients who were eligible for NGS at diagnosis and after chemotherapies. We detected germline variants in 19 patients (5.5%). The most frequent germline mutations were in DDX41 (n=11, 58%) followed by DNAH5 (n=3, 16%), CEBPA and TP53 (both n=2, 11%), and MPL and GATA2 (both n=1, 5%). One patient harbored both TP53 and DNAH5 germline mutations. The mean VAF at diagnosis and CR samples were 48.9% [inter-quantile range (IQR): 47.8%-49.9%] and 48.0% (IQR: 47.6%-49.7%) respectively. Compared with non-germline mutated patients, patients with germline mutations were more hypoplastic (50% vs 80%, P < 0.001), and low bone marrow blast counts (34% vs. 65%, P=0.004). Germline mutations were not observed in the favorable cytogenetic risk group (0% vs. 23.1%, P= 0.03), and were rarely detected in 2022 European LeukemiaNet favorable risk group (5.3% vs. 47.5%, P <0.001), compared with non-germline mutated patients. Intensive chemotherapy was more frequently administered in the non-germline mutated group (P=0.022) but, there was no difference in the rate of allogeneic transplants between the two groups (P>0.05). Comparing survival rates, there was no difference between two groups that received intensive chemotherapy, nor was there a difference for those who underwent allogeneic transplantation (all, P>0.05).

In conclusion, NGS analysis using matched CR samples proves to be an invaluable tool in detecting germline mutations. Since patients with germline mutations are rarely classified into the favorable risk category, most patients in this group should consider allogeneic transplantation. Although patients with germline mutations did not show significant prognostic differences in treatment outcomes due to the small number of patients, more studies involving a larger cohort are needed to determine the role of allogeneic transplantation.

Disclosures: Lee: NGnebio: Current Employment. Kim: BMS & Celgene, Novartis, APLC, AbbVie, Astellas, Janssen, Handok, Pfizer, Sanofi Genzyme, AML-Hub, Daiichi Sankyo and APBMT: Membership on an entity's Board of Directors or advisory committees; AbbVie, Astellas, BMS, Handok, Novartis, AML-Hub, Jazz Pharmaceuticals and Takeda: Honoraria, Speakers Bureau; AbbVie, AIMS Bioscience, AML-Hub, Astellas, BMS & Celgene, Boryung Pharm Co., Daiichi Sankyo, Janssen, Handok, LG Chem, Novartis, Pfizer, SL VaxiGen, VigenCell, Aston Bioscience, Ingenium, Amgen, Sanofi Genzyme, Takeda, Meiji Pharm Co. and GreenCross Phar: Consultancy; AML-Hub, APBMT, ICBMT, APLC, Novartis and BMS: Other: and leadership or fiduciary roles in other board, society, committee or advocacy group ; Jazz Pharmaceuticals, Takeda, Astellas, AbbVie and APLC: Other: Travel; BL&H: Research Funding.

*signifies non-member of ASH